Medi-Caps Limited (BOM:523144)
India · Delayed Price · Currency is INR 26.82
+0.59 (2.25%)
At close: Jul 31, 2026
Medi-Caps Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 124.49 | 124.49 | 254.77 | 273.45 | 493.71 | 698.71 |
Revenue Growth | -51.14% | -51.14% | -6.83% | -44.61% | -29.34% | 18.99% |
Gross Profit Gross Profit Growth | 49.19 | 49.19 | 148.26 | 178.28 | 264.66 | 397.61 |
Operating Income Operating Income Growth | -112.18 | -112.18 | -35.46 | -17.21 | 33.19 | 82.04 |
Net Income Net Income Growth | -30.38 | -30.38 | -5.71 | -22.41 | 17.56 | 100.81 |
Earnings Per Share EPS Growth | -2.44 | -2.44 | -0.46 | -1.80 | 1.41 | 8.08 |
EPS Growth | - | - | - | - | -82.58% | -9.47% |
Revenue by Segment
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharma Division Pharma Division Growth | 101.43 | 101.43 | 230.61 | 205.08 | 502.28 | 711.78 |
Real Estate Division Real Estate Division Growth | 23.06 | 23.06 | 24.17 | 73.13 | 7.46 | 6.07 |
Total Total Growth | 124.49 | 124.49 | 254.77 | 278.2 | 509.74 | 717.85 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 239.14 | 239.14 | 342.09 | 356.28 | 362.42 | 367.11 |
Total Debt Total Debt Growth | - | - | - | - | - | - |
Net Cash (Debt) Net Cash Growth | 239.14 | 239.14 | 342.09 | 356.28 | 362.42 | 367.11 |
Net Cash Growth | -30.09% | -30.09% | -3.98% | -1.70% | -1.28% | 10.90% |
Net Cash Per Share Net Cash Per Share Growth | 19.21 | 19.21 | 27.43 | 28.57 | 29.06 | 29.44 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -70.22 | -70.22 | 50.69 | 69.39 | -60.81 | 70.21 |
Capital Expenditures CapEx Growth | -8.46 | -8.46 | -3.26 | -3.46 | -11.63 | -27.94 |
Free Cash Flow Free Cash Flow Growth | -78.69 | -78.69 | 47.43 | 65.93 | -72.44 | 42.28 |
Free Cash Flow Growth | - | - | -28.06% | - | - | -67.64% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 39.51% | 39.51% | 58.19% | 65.20% | 53.61% | 56.91% |
Operating Margin | -90.12% | -90.12% | -13.92% | -6.29% | 6.72% | 11.74% |
Pretax Margin | -24.29% | -24.29% | -3.30% | -4.56% | 9.97% | 14.39% |
Profit Margin | -24.40% | -24.40% | -2.24% | -8.20% | 3.56% | 14.43% |
FCF Margin | -63.21% | -63.21% | 18.62% | 24.11% | -14.67% | 6.05% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | - | - | 24.81 | 6.14 |
P/FCF Ratio | - | - | 10.91 | 8.39 | - | 14.65 |
PS Ratio | 2.69 | 2.32 | 2.03 | 2.02 | 0.88 | 0.89 |